Drugs / XBI-302
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05352269 | Apr → Aug 2022 | acute graft versus host disease | Shenzhen Xbiome Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05001360 | Oct 2021 → Oct 2023 | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Fujian Cancer Hospital | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-09-14 | Shenzhen Xbiome Biotech Co., Ltd. | Regulatory 未知君FMT药物获得美国FDA临床试验批准 xbiome.com ↗
近日，未知君研发的一款代号为“XBI-302”的粪菌移植药物（后简称“FMT药物”），获得了美国食品药品监督管理局（后简称“FDA”）的新药临床试验（后简称“IND”）批准，可正式进入治疗急性移植物抗宿主病的临床试验阶段。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-09-14 | Shenzhen Xbiome Biotech Co., Ltd. | 未知君FMT药物获得美国FDA临床试验批准 xbiome.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XBI-302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05352269 ↗ |
| Route | Oral | “FMT capsules XBI-302 will be administered orally” NCT05001360 ↗ |